<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>SLS</title></head><body><div><p style="margin:0pt; text-align:justify"><span style="font-family:Arial; font-size:10pt">              </span><span style="font-family:Arial; font-size:10pt">              </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Arial; font-size:10pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by Discuva Ltd (AMR0044)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">I give the answers below in response to the following questions:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">How has antimicrobial resistance developed in the past decade?</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">What are the gaps in our knowledge about antimicrobial resistance?</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified?</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">What measures (including behavioural change) have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens?</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">What global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">What are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Answers (from David Williams, CEO and representative of Discuva Ltd)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The biggest change over the past decade has been the rise of antimicrobial resistance to Gram-negative bacteria, due to widespread inappropriate use of broad-spectrum antibiotics. These pathogens are now a major risk for hospital-acquired infection including systemic ‘line’ derived and respiratory infections. Groups currently most at risk include aging patients exposed to joint replacement operations, long-term diabetics and cancer patients undergoing chemotherapy or longer term palliative care.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> We’re also seeing an increase in drug-resistant community Gram-negative infections including </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">E.coli</span><span style="font-family:'Times New Roman'; font-size:11pt"> in urinary tract infections </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">and Neisseria gonorrhoeae</span><span style="font-family:'Times New Roman'; font-size:11pt"> in sexually-transmitted disease</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We do need more whole genome tracking of drug-resistant infection spread (i.e. the more widespread use and method development for next generation sequencing and the associated bio-informatics support and databases). A recent small study in this area actually found the cause of such an infection and prevented its further spread.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> Use of this technology would allow us to more clearly trace and understand the reasons and mode of resistance spread. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">This is a difficult question for us to answer as we believe we have the most advance new antibiotic discovery platform in the world capable of continually supplying new antibiotics to the world as required.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> We are growing organically from investment and Pharmaceutical company collaboration, but still relatively small, so accelerated investment in our company would ultimately improve the situation for new drugs.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> The overall investment in this field has been very low and the commercial drivers poor. The new drugs need to be priced to reflect the research and development expense and actually prescribed.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> We have a current situation where a drug approved by NICE for the treatment of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C.difficile</span><span style="font-family:'Times New Roman'; font-size:11pt"> infection, which prevents re-infection, so cures the patient, still isn’t widely used, because it costs ~£1500 for a 10-day treatment.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> The alternative more-widely used treatments are either Metronidazole and Vancomycin, which are toxic and have the risk of not preventing reoccurrence.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> In addition, use of Vancomycin leads to a higher risk of generating other pathogens resistant to this antibiotic of last </span><span style="font-family:'Times New Roman'; font-size:11pt">resort</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The biggest improvement here would be to change the behaviour of the clinician tier in the healthcare system.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> We need to get rid of the ‘I’m god’ attitude.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> Only last month I saw a consultant oncologist treat a </span><a name="_GoBack"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C.difficile</span></a><span style="font-family:'Times New Roman'; font-size:11pt">-infected patient, when walk out of the room without washing their hands on their way to another uninfected patient (having not washed their hands on the way in either). Contracted ward cleaning is also a disaster, so hospital-employed ward controlled cleaning should be re-established, going back to the days of hospitals which are clean and smell of bleach. The risk in the current system is the high turnaround in casual labour staff bringing cleaners to the ward that do not follow rigid infection control practices. An example of this I saw recently was a contract worker cleaning a toilet then using the same cloth used to clean around the toilet bowl to clean the table top used by a patient for eating.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Resistance surveillance around the world is extremely patchy with the best system currently operating in Europe. Even the US does not have a joined-up system, so it’s currently extremely difficult to see how a global system would work without first internal investment within co-ordinating countries</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">I haven’t yet read this plan (only recently found out about it). My comment would be that we’ve found most, if not all current government-led organisations in the sector keen to help, but totally dysfunctional in terms of doing anything at speed. Government-sponsored scientists in this area generally lack operational experience or are just poor quality. Academic advisors are not outward facing enough so should not advise on patient care or strategy.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> Clinicians lack the scientific knowledge (i.e the breath of truly new developments in the area) and the health economic components. Managerial decision making is a rare quality and committees seem to form whenever it’s daylight. This whole area has suffered from a lack of investment so all the truly inspirational thinkers went elsewhere.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> Attracting good people back into the area needs a very big rethink.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> The role of a ‘microbiologist’ needs to be redefined at the university/medical school level with cross fertilisation from other disciplines (i.e. cancer).</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> The other thing we need to do is change the crazy situation where medics run screening laboratories and put them back in front of patients, replacing them with good medical scientists. This change would accelerate development in the field removing a very conservative block and improving the quality of the output.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Arial; font-size:10pt">&#xa0;</span></p></div></body></html>